WO2005103684A3 - Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) - Google Patents

Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) Download PDF

Info

Publication number
WO2005103684A3
WO2005103684A3 PCT/EP2005/004018 EP2005004018W WO2005103684A3 WO 2005103684 A3 WO2005103684 A3 WO 2005103684A3 EP 2005004018 W EP2005004018 W EP 2005004018W WO 2005103684 A3 WO2005103684 A3 WO 2005103684A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cx3cr1
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/004018
Other languages
French (fr)
Other versions
WO2005103684A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005103684A2 publication Critical patent/WO2005103684A2/en
Publication of WO2005103684A3 publication Critical patent/WO2005103684A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a human CX3CR1 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, cancer, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, cancer, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CX3CR1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/004018 2004-04-20 2005-04-15 Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) WO2005103684A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04009259 2004-04-20
EP04009259.5 2004-04-20

Publications (2)

Publication Number Publication Date
WO2005103684A2 WO2005103684A2 (en) 2005-11-03
WO2005103684A3 true WO2005103684A3 (en) 2006-03-09

Family

ID=35045005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004018 WO2005103684A2 (en) 2004-04-20 2005-04-15 Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)

Country Status (1)

Country Link
WO (1) WO2005103684A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1841887A2 (en) * 2005-01-19 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Cx3cr1 as a marker which correlates with both disease and disease activity in multiple sclerosis patients
MD4548C1 (en) 2012-02-27 2018-08-31 Boehringer Ingelheim International Gmbh CX3CR1-binding polypeptides
EP2820426A4 (en) 2012-03-01 2015-07-29 Univ California Novel target for diagnosis and treatment of diabetes and cardiovascular diseases
JP2016534114A (en) * 2013-08-21 2016-11-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CX3CR1 targeted imaging agent and its use in disease diagnosis and treatment
CN111773386A (en) * 2019-04-03 2020-10-16 中国科学院深圳先进技术研究院 Alzheimer disease treatment target
CN116173034A (en) * 2023-03-30 2023-05-30 南通大学 Use of CX3CR1 antagonists for the manufacture of a medicament for the treatment of cognitive disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104484A1 (en) * 2002-06-10 2003-12-18 Metabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104484A1 (en) * 2002-06-10 2003-12-18 Metabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMAI T ET AL: "Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 91, 14 November 1997 (1997-11-14), pages 521 - 530, XP002970589, ISSN: 0092-8674 *
MOATTI D ET AL: "Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 91, no. 7, 1 April 2001 (2001-04-01), pages 1925 - 1928, XP002970592, ISSN: 0006-4971 *
WONG BRIAN W C ET AL: "Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease.", CARDIOVASCULAR PATHOLOGY : THE OFFICIAL JOURNAL OF THE SOCIETY FOR CARDIOVASCULAR PATHOLOGY. 2002 NOV-DEC, vol. 11, no. 6, November 2002 (2002-11-01), pages 332 - 338, XP009055403, ISSN: 1054-8807 *

Also Published As

Publication number Publication date
WO2005103684A2 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2005101011A3 (en) Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase